Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Tolerability and Pharmacokinetic Study of Single and Repeat Oral Escalating Doses of Simmiparib in Patients With Advanced Malignant Tumors

NCT02993913 is registered in ClinicalTrials.gov with Shanghai Acebright Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT02993913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Tolerability and Pharmacokinetic Study of Single and Repeat Oral Escalating Doses of Simmiparib in Patients With Advanced Malignant Tumors
Lead sponsor
Shanghai Acebright Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2016
Completion date
Not reported
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant advanced solid tumor